BioSig Technologies, Inc. (NASDAQ:BSGM – Get Rating) – Equities research analysts at Taglich Brothers lifted their Q2 2023 EPS estimates for shares of BioSig Technologies in a research note issued on Wednesday, May 31st. Taglich Brothers analyst H. Halpern now anticipates that the company will earn ($0.08) per share for the quarter, up from their previous forecast of ($0.09). Taglich Brothers has a “Speculative Buy” rating on the stock. The consensus estimate for BioSig Technologies’ current full-year earnings is ($0.35) per share. Taglich Brothers also issued estimates for BioSig Technologies’ Q3 2023 earnings at ($0.08) EPS, Q4 2023 earnings at ($0.07) EPS, FY2023 earnings at ($0.35) EPS, Q3 2024 earnings at ($0.06) EPS and FY2024 earnings at ($0.26) EPS.
Separately, Ascendiant Capital Markets started coverage on shares of BioSig Technologies in a research note on Monday, February 13th. They issued a “buy” rating and a $5.00 price objective for the company.
BioSig Technologies Stock Down 7.7 %
Institutional Investors Weigh In On BioSig Technologies
A number of hedge funds and other institutional investors have recently modified their holdings of BSGM. Nicolet Advisory Services LLC acquired a new position in BioSig Technologies during the first quarter valued at approximately $27,000. Jane Street Group LLC acquired a new stake in BioSig Technologies in the fourth quarter worth about $29,000. Mayo Clinic acquired a new stake in BioSig Technologies in the 4th quarter valued at about $42,000. FAS Wealth Partners Inc. lifted its holdings in BioSig Technologies by 50.0% in the 1st quarter. FAS Wealth Partners Inc. now owns 45,000 shares of the company’s stock valued at $51,000 after acquiring an additional 15,000 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its holdings in BioSig Technologies by 9.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 137,705 shares of the company’s stock valued at $57,000 after acquiring an additional 12,000 shares during the last quarter. 9.06% of the stock is currently owned by hedge funds and other institutional investors.
About BioSig Technologies
BioSig Technologies, Inc is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures.
Featured Stories
- Get a free copy of the StockNews.com research report on BioSig Technologies (BSGM)
- MarketBeat Week in Review – 5/29 – 6/2
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
